Почетна › Интерстицијални белодробни болести › Тексас
Клинички испитувања за Интерстицијални белодробни болести во Тексас
18 студии за Интерстицијални белодробни болести бараат учесници на локации во Тексас.
Градови во Тексас
Официјален текст на студијата (англиски)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Baylor University Medical Center, Dallas
- Metroplex Pulmonary & Sleep Center, McKinney
- UT Health San Antonio, San Antonio
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Baylor College of Medicine, Houston
Се регрутираФаза 3
Возраст 40 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07201922LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Stryde Research, Carrollton
- Baylor University Medical Center, Dallas
- Discovery Clinical Trials, San Antonio
- и уште 1
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 29.9.2026 · NCT05798923A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Houston
- GSK Investigational Site, Temple
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Denison
- GSK Investigational Site, El Paso
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- El Paso Pulmonary Association, El Paso
- Baylor College of Medicine, Houston
- Baylor Scott and White Health, Temple
Се регрутираФаза 2
Возраст 40 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Baylor University Medical Center, Dallas
- Baylor College of Medicine, Houston
- Houston Methodist Hospital, Houston
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Houston
Се регрутираФаза 2
Возраст од 18 до 85 · Сите полови · Ажурирано 2.9.2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Baylor University Medical Center, Dallas
- UT Southwest Medical Center Heart and Lung Clinic, Dallas
- Houston Methodist, Houston
- и уште 1
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Texas Southwestern, Dallas
Се регрутираНабљудувачка студија
Возраст од 18 до 80 · Сите полови · Ажурирано 18.8.2026 · NCT06855329Platform Clinical Study for Conquering Scleroderma
- University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT06195072Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Texas Southwestern, Dallas
- Baylor University Medical Center at Dallas, Dallas
- Baylor College of Medicine, Houston
- и уште 2
Се регрутираНабљудувачка студија
Возраст 21 и постари · Сите полови · Ажурирано 12.8.2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Houston Methodist Hospital, Houston
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 10.8.2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center-Advanced Lung Clinic, Dallas
- Houston Methodist Outpatient Center, Houston
- и уште 4
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT05943535TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
- Baylor College of Medicine/Texas Children'S Hospital, Houston
Се регрутираНабљудувачка студија
До возраст 24 · Сите полови · Ажурирано 22.6.2026 · NCT04098445A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Galderma Investigational Site#7096, Arlington
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 31.3.2026 · NCT07047690Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- University of Texas Southwestern Medical Center, Dallas
- Metroplex Pulmonary and Sleep Center, McKinney
- Research Centers of America, McKinney
Се регрутираФаза 2
Возраст 40 и постари · Сите полови · Ажурирано 12.11.2025 · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Dallas
- aTyr Investigative Site, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 7.5.2025 · NCT05892614Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.